WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY® 04 January 2021
Pfizer and BioNTech to supply the U.S. with 100 million additional doses of COVID-19 vaccine 23 December 2020
Pfizer and BioNTech receive authorization in the European Union for COVID-19 vaccine 21 December 2020
Pfizer and BioNTech receive CHMP positive opinion for their COVID-19 vaccine 21 December 2020
Pfizer and BioNTech celebrate historic first authorization in the U.S. of vaccine to prevent COVID-19 14 December 2020
Pfizer and BioNTech receive FDA Advisory Committee vote supporting potential first Emergency Use Authorization for vaccine to combat COVID-19 in the U.S. 11 December 2020
Pfizer and BioNTech announce publication of results from landmark Phase 3 trial of BNT162b2 COVID-19 vaccine candidate in The New England Journal of Medicine 10 December 2020
Pfizer and BioNTech achieve Health Canada authorization for their vaccine to combat COVID-19 09 December 2020
Pfizer and BioNTech achieve first authorization in the world for a vaccine to combat COVID-19 02 December 2020
Pfizer and BioNTech to submit Emergency Use Authorization request today to the U.S. FDA for COVID-19 vaccine 20 November 2020
Pfizer and BioNTech conclude Phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints 18 November 2020
Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study 09 November 2020
BioNTech and Pfizer initiate rolling submission to European Medicines Agency for SARS-CoV-2 vaccine candidate BNT162b2 06 October 2020
Pfizer and BioNTech propose expansion of pivotal COVID-19 vaccine trial 14 September 2020
Pfizer and BioNTech announce data from preclinical studies of mRNA-based vaccine candidate against COVID-19 09 September 2020
Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162b2 against COVID-19 21 August 2020
Pfizer announces agreement with Gilead to manufacture remdesivir for treatment of COVID-19 11 August 2020
Pfizer and BioNTech to supply Japan with 120 million doses of their BNT162 mRNA-based vaccine candidate 31 July 2020
Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal Phase 2/3 global study 28 July 2020
Pfizer and BioNTech announce an agreement with U.S. Government for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2 27 July 2020
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End

Business & Industry

  • Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
  • Pfizer and BioNTech publish results of study showing COVID-19 vaccine elicits antibodies that neutralize pseudovirus bearing the SARS-CoV-2 U.K. strain spike protein
  • Roche confirms US government agreement to purchase additional doses of Regeneron's casirivimab and imdevimab
  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare

Research & Development

  • COVAX announces new agreement, plans for first deliveries
  • Obesity, impaired metabolic health and COVID-19
  • COVID-19 has multiple faces
  • Metformin use reduces risk of death for patients with COVID-19 and diabetes
  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech to supply the European Union with 100 million additional doses of COMIRNATY®

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.